CERAGENIX PRESENTS POSITIVE DATA ON ITS NOVEL ANTIMICROBIAL MEDICAL DEVICE COATING AT INTERNATIONAL CONFERENCE ON INFECTIOUS DISEASES

Ceragenix Pharmaceuticals, Inc., a development stage biopharmaceutical company, today announced that it presented in vitro data at a leading international conference on infectious disease. In its presentation, Ceragenix showed that its novel antimicrobial device coating, when challenged in separate experiments by high levels of staphylococcus aureus and E. Coli, was highly effective in completely preventing bacterial colonization on titanium surfaces and in eradicating the bacteria in the surrounding fluid. The data was presented in one of five poster presentations on Ceragenix's cationic steroid antibiotic ("CSA") technology at the ICAAC conference held in Washington, DC, December 16th to 20th.

Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=1130427XSL_NEWSML_TO_NEWSML_WEB.xml)